OUR PURPOSE PIONEERING SCIENCE PATIENTS OUR PEOPLE ENVIRONMENT COMMUNITY REPORTING 44 ADVANCING HEALTH ACCESS AND EQUITY BIOGEN 2021 YEAR IN REVIEW – In Saudi Arabia, our SMA Risk Sharing Agreement went into effect in early 2021. The comprehensive program in partnership with the local authorities ensures patients are identified, diagnosed, treated and followed up with in a timely manner and that care is delivered from fully approved centers of excellence and strong multi- disciplinary teams. – Through the renewal process, we were able to expand and maintain access to SPINRAZA for SMA patients in a number of countries. BIOGEN PRICING PRINCIPLES Value to patients Present and Future Benefit to Society Fulfilling our Commitment to Innovation Evolution Toward Value- Based Care Affordability and Sustainability Þ PLEASE SEE OUR PRICING PRINCIPLES Promoting health equity Biogen is committed to addressing inequities across the healthcare ecosystem, from research and clinical trials to equitable access and culturally competent care. This commitment starts from how we work. Engaging employees We routinely foster employee collaboration in an effort to achieve health equity, with a focus on impact. In 2021, we introduced a Health Equity Ideas Cafe Series to deepen organization-wide understanding and action on Biogen’s commitment, including representation in our clinical trials and equitable access. The three-part series engaged internal and external guest speakers on themes of lupus awareness, patient voices and community partnerships, and equitable access. In addition, we hosted a lunch and learn with John Sawyer, Ph.D., ABPP-CN and a board- certified clinical neuropsychologist of the Ochsner Neuroscience Institute; and Donnie Batie, M.D., both members of the Alzheimer’s disease underrepresented population working group, on successful approaches to caring for underrepresented patients. We continued the underserved and underrepresented (UP) Champions program with participation from different functions to build and execute initiatives both internally and externally that will ensure representation in Biogen clinical trials. A multi-pronged approach We strive to take a holistic approach to patient health and better understand patient needs or emerging issues. To do so, we engaged external stakeholders in three distinct Health Equity Advisory Boards focused on the following areas: – Access: to understand and overcome barriers to accessing therapies. – Clinical trials: to ensure clinical trials are reflective of the target population. – Policies: to consider policies that support equity with access to participation in clinical trials and Biogen therapies.